Abstract | PURPOSE: METHODS:
Cediranib, an oral pan- VEGF receptor tyrosine kinase inhibitor, was administered (45 mg/d) until progression or unacceptable toxicity to patients with recurrent glioblastoma. The primary end point was the proportion of patients alive and progression free at 6 months (APF6). We performed magnetic resonance imaging (MRI) and plasma and urinary biomarker evaluations at multiple time points. RESULTS: CONCLUSION:
Cediranib monotherapy for recurrent glioblastoma is associated with encouraging proportions of radiographic response, 6-month progression-free survival, and a steroid-sparing effect with manageable toxicity. We identified early changes in circulating molecules as potential biomarkers of response to cediranib. The efficacy of cediranib and the predictive value of these candidate biomarkers will be explored in prospective trials.
|
Authors | Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Scott R Plotkin, Elizabeth Gerstner, April F Eichler, Jan Drappatz, Fred H Hochberg, Thomas Benner, David N Louis, Kenneth S Cohen, Houng Chea, Alexis Exarhopoulos, Jay S Loeffler, Marsha A Moses, Percy Ivy, A Gregory Sorensen, Patrick Y Wen, Rakesh K Jain |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 28
Issue 17
Pg. 2817-23
(Jun 10 2010)
ISSN: 1527-7755 [Electronic] United States |
PMID | 20458050
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Biomarkers, Tumor
- Protein Kinase Inhibitors
- Quinazolines
- Receptors, Vascular Endothelial Growth Factor
- cediranib
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Biomarkers, Tumor
(blood)
- Brain Neoplasms
(blood, drug therapy, enzymology, pathology)
- Disease-Free Survival
- Female
- Glioblastoma
(blood, drug therapy, enzymology, pathology)
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(blood, drug therapy, enzymology)
- Protein Kinase Inhibitors
(adverse effects, therapeutic use)
- Quinazolines
(adverse effects, therapeutic use)
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors)
- Young Adult
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|